Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2.

Bembenek SD, Venkatesan H, Peltier HM, Rosen MD, Barrett TD, Kanelakis KC, Palomino HL, Brondstetter TI, Mirzadegan T, Rabinowitz MH.

ACS Omega. 2019 Apr 30;4(4):6703-6708. doi: 10.1021/acsomega.9b00199. Epub 2019 Apr 12.

2.

Polarization Oscillations in Birefringent Emitter-Cavity Systems.

Barrett TD, Barter O, Stuart D, Yuen B, Kuhn A.

Phys Rev Lett. 2019 Mar 1;122(8):083602. doi: 10.1103/PhysRevLett.122.083602.

PMID:
30932599
3.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

4.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B.

Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.

5.

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.

Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B.

Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.

6.

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats.

Barrett TD, Palomino HL, Brondstetter TI, Kanelakis KC, Wu X, Yan W, Merton KP, Schoetens F, Ma JY, Skaptason J, Gao J, Tran DT, Venkatesan H, Rosen MD, Shankley NP, Rabinowitz MH.

Br J Pharmacol. 2015 Aug;172(16):4078-88. doi: 10.1111/bph.13188. Epub 2015 Jun 26.

7.

The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.

Barrett TD, Lagaud G, Wagaman P, Freedman JM, Yan W, Andries L, Rizzolio MC, Morton MF, Shankley NP.

Br J Pharmacol. 2012 Jul;166(5):1684-93. doi: 10.1111/j.1476-5381.2012.01878.x.

8.

JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.

Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K, Cagnon L, Lagaud G, Ver Donck L, Ghoos E, Allison B, Rabinowitz MH, Shankley NP.

J Pharmacol Exp Ther. 2011 Jul;338(1):328-36. doi: 10.1124/jpet.110.178483. Epub 2011 Apr 14.

PMID:
21493750
9.

Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer.

Morton M, Prendergast C, Barrett TD.

Trends Pharmacol Sci. 2011 Apr;32(4):201-5. doi: 10.1016/j.tips.2011.02.003. Epub 2011 Mar 10.

PMID:
21397342
10.

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor.

Barrett TD, Palomino HL, Brondstetter TI, Kanelakis KC, Wu X, Haug PV, Yan W, Young A, Hua H, Hart JC, Tran DT, Venkatesan H, Rosen MD, Peltier HM, Sepassi K, Rizzolio MC, Bembenek SD, Mirzadegan T, Rabinowitz MH, Shankley NP.

Mol Pharmacol. 2011 Jun;79(6):910-20. doi: 10.1124/mol.110.070508. Epub 2011 Mar 3.

PMID:
21372172
11.

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues.

Rosen MD, Venkatesan H, Peltier HM, Bembenek SD, Kanelakis KC, Zhao LX, Leonard BE, Hocutt FM, Wu X, Palomino HL, Brondstetter TI, Haugh PV, Cagnon L, Yan W, Liotta LA, Young A, Mirzadegan T, Shankley NP, Barrett TD, Rabinowitz MH.

ACS Med Chem Lett. 2010 Oct 5;1(9):526-9. doi: 10.1021/ml100198y. eCollection 2010 Dec 9.

12.

Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase.

Rosen MD, Woods CR, Goldberg SD, Hack MD, Bounds AD, Yang Y, Wagaman PC, Phuong VK, Ameriks AP, Barrett TD, Kanelakis KC, Chuang JC, Shankley NP, Rabinowitz MH.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6548-51. doi: 10.1016/j.bmcl.2009.10.033. Epub 2009 Oct 13. Erratum in: Bioorg Med Chem Lett. 2010 Jun 15;20(12):3834. Chang, Jui [corrected to Chuang, Jui Chang].

PMID:
19854648
13.

Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.

Pippel M, Boyce K, Venkatesan H, Phuong VK, Yan W, Barrett TD, Lagaud G, Li L, Morton MF, Prendergast C, Wu X, Shankley NP, Rabinowitz MH.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6376-8. doi: 10.1016/j.bmcl.2009.09.065. Epub 2009 Sep 23.

PMID:
19815410
14.

Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases.

Kanelakis KC, Palomino HL, Li L, Wu J, Yan W, Rosen MD, Rizzolio MC, Trivedi M, Morton MF, Yang Y, Venkatesan H, Rabinowitz MH, Shankley NP, Barrett TD.

J Biomol Screen. 2009 Jul;14(6):627-35. doi: 10.1177/1087057109333976. Epub 2009 Jun 4.

PMID:
19498081
15.

Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction.

Barrett TD, Yan W, Freedman JM, Lagaud GJ, Breitenbucher JG, Shankley NP.

Br J Pharmacol. 2008 Apr;153(8):1650-8. doi: 10.1038/bjp.2008.44. Epub 2008 Feb 25.

16.

Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.

Rosen MD, Hack MD, Allison BD, Phuong VK, Woods CR, Morton MF, Prendergast CE, Barrett TD, Schubert C, Li L, Wu X, Wu J, Freedman JM, Shankley NP, Rabinowitz MH.

Bioorg Med Chem. 2008 Apr 1;16(7):3917-25. doi: 10.1016/j.bmc.2008.01.059. Epub 2008 Feb 5.

PMID:
18289861
17.

Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands.

Woods CR, Hack MD, Allison BD, Phuong VK, Rosen MD, Morton MF, Prendergast CE, Barrett TD, Shankley NP, Rabinowitz MH.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6905-9. Epub 2007 Sep 29.

PMID:
18029172
18.

SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists.

Gomez L, Hack MD, McClure K, Sehon C, Huang L, Morton M, Li L, Barrett TD, Shankley N, Breitenbucher JG.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6493-8. Epub 2007 Oct 1.

PMID:
17933530
19.

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.

Hong TT, Huang J, Barrett TD, Lucchesi BR.

Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H145-55. Epub 2007 Oct 5.

20.

3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.

Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP.

J Pharmacol Exp Ther. 2007 Nov;323(2):562-9. Epub 2007 Aug 7.

PMID:
17684117
21.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.

Plouvier B, Beatch GN, Jung GL, Zolotoy A, Sheng T, Clohs L, Barrett TD, Fedida D, Wang WQ, Zhu JJ, Liu Y, Abraham S, Lynn L, Dong Y, Wall RA, Walker MJ.

J Med Chem. 2007 Jun 14;50(12):2818-41. Epub 2007 May 17.

PMID:
17506538
22.

Obestatin reduces food intake and suppresses body weight gain in rodents.

Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP.

Biochem Biophys Res Commun. 2007 May 25;357(1):264-9. Epub 2007 Mar 30. Retraction in: Biochem Biophys Res Commun. 2009 Oct 23;388(3):619.

PMID:
17418097
23.

Effect of sodium/hydrogen exchange inhibition on myocardial infarct size after coronary artery thrombosis and thrombolysis.

Hennan JK, Driscoll EM, Barrett TD, Fischbach PS, Lucchesi BR.

Pharmacology. 2006;78(1):27-37. Epub 2006 Apr 3.

PMID:
16899991
24.

A novel, quantitative bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised rat.

Freedman JM, Barrett TD, Shankley NP.

J Pharmacol Toxicol Methods. 2006 Jul-Aug;54(1):36-41. Epub 2005 Oct 24.

PMID:
16246596
25.

Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity.

McClure K, Hack M, Huang L, Sehon C, Morton M, Li L, Barrett TD, Shankley N, Breitenbucher JG.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):72-6. Epub 2005 Oct 19.

PMID:
16236513
26.

Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity.

Sehon C, McClure K, Hack M, Morton M, Gomez L, Li L, Barrett TD, Shankley N, Breitenbucher JG.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):77-80. Epub 2005 Oct 19.

PMID:
16236506
27.

Mechanism of tissue-selective drug action in the cardiovascular system.

Barrett TD, Triggle DJ, Walker MJ, Maurice DH.

Mol Interv. 2005 Apr;5(2):84-93. Review.

PMID:
15821157
28.

Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel.

Fischbach PS, White A, Barrett TD, Lucchesi BR.

J Pharmacol Exp Ther. 2004 May;309(2):554-9. Epub 2004 Jan 27.

PMID:
14747611
29.
30.

SNC-80-induced preconditioning: selective activation of the mitochondrial adenosine triphosphate-gated potassium channel.

Fischbach PS, Barrett TD, Reed NJ, Lucchesi BR.

J Cardiovasc Pharmacol. 2003 May;41(5):744-50.

PMID:
12717105
31.

C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion.

Barrett TD, Hennan JK, Marks RM, Lucchesi BR.

J Pharmacol Exp Ther. 2002 Dec;303(3):1007-13.

PMID:
12438521
32.

Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.

Fischbach PS, Barrett TD, Goyal R, Tran BC, Syed ZA, Hennan JK, Lucchesi BR.

J Cardiovasc Electrophysiol. 2001 Oct;12(10):1138-44.

PMID:
11699522
33.

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR.

Circulation. 2001 Aug 14;104(7):820-5.

PMID:
11502709
34.

Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.

Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll EM Jr, Lucchesi BR.

Br J Pharmacol. 2001 Apr;132(7):1493-500.

35.
36.

Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats.

Barrett TD, Hayes ES, Yong SL, Zolotoy AB, Abraham S, Walker MJ.

Eur J Pharmacol. 2000 Jun 23;398(3):365-74.

PMID:
10862826
38.

A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits.

Barrett TD, MacLeod BA, Walker MJ.

J Pharmacol Toxicol Methods. 1997 Feb;37(1):27-36.

PMID:
9086286
39.

Effects of halothane and isoflurane on rat ventricular action potentials recorded in situ.

Hayes ES, Barrett TD, Burrill DE, Walker MJ.

Life Sci. 1996;58(16):1375-85.

PMID:
8614295

Supplemental Content

Loading ...
Support Center